[29] have found high expression of both AR and NE markers in a small subset of prostate cancer patients, especially among CRPC cases, suggesting AR might still exert its androgen response and anti-apoptotic effects in these patients which might be related to CRPC progression. The gene discussed is AR; the disease is prostate carcinoma.